Key result
Dabigatran and rivaroxaban dose-dependently inhibit coagulation factors II, V, VIII, and X.
Why the study?
The study was conducted to explore the effects of dabigatran and rivaroxaban on the activities of various coagulation factors.
p-value: p=<0.001
Dabigatran and rivaroxaban exhibit distinct, dose-dependent inhibitory effects on specific coagulation factors and coagulation times in a rabbit model.
Caution against extrapolating rabbit data to patients; extends preclinical understanding of dose-dependent factor inhibition by these anticoagulants.
The aim of this study was to explore the effects of dabigatran and rivaroxaban on the activities of various coagulation factors. To achieve that, 60 rabbits were randomly divided into experimental groups that received different doses of dabigatran or rivaroxaban. The effects of dabigatran and rivaroxaban on the activities of FII, FV, FVIII, FX, and activated protein C (APC) were analyzed. In the dabigatran groups, activated partial thromboplastin time and thromboplastin time (TT) were prolonged after drug administration, and the activities of FII, FV, FVIII, and FX were inhibited as the drug concentration increased. Low doses of dabigatran inhibited APC activity. In the rivaroxaban groups, APTT and TT were not significantly prolonged after drug administration. In contrast, the high-dose rivaroxaban group exhibited prolonged PT, and the degree of inhibition of the activities of FII, FV, FVIII, and FX increased as the drug concentration increased. Rivaroxaban had no significant effect on APC activity regardless of dosage. As the drug concentration increased, both NOACs had more significant inhibitory effects on the activities of FII, FV, FVIII, and FX. Low concentrations of dabigatran generated an inhibitory effect on APC activity, while high concentrations of dabigatran had no significant effect. Rivaroxaban had no significant effect on APC activity.
No takes yet. Share an insight, caveat, or question.
Yin et al. (2022) studied Healthy animals (blood coagulation assessment) (n=60). Dabigatran and Rivaroxaban vs. Solvent or distilled water (blank control) was evaluated on Activities of coagulation factors FII, FV, FVIII, FX, and activated protein C (APC) (p=<0.001). Both dabigatran and rivaroxaban dose-dependently inhibited the activities of coagulation factors II, V, VIII, and X in healthy rabbits.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: